Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2016

  • ID: 3946382
  • Drug Pipelines
  • 665 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AB Science SA
  • Arno Therapeutics, Inc.
  • CellCentric Ltd
  • G1 Therapeutics, Inc.
  • Johnson & Johnson
  • Orion Oyj
  • MORE
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2016

Summary

Our latest Pharmaceutical and Healthcare disease pipeline guide Hormone Refractory Prostate Cancer - Pipeline Review, H2 2016, provides an overview of the Hormone Refractory Prostate Cancer (Oncology) pipeline landscape.

Prostate cancer no longer responds to hormone therapy and growth of the cancer continues, it is called hormone resistant or hormone refractory prostate cancer. This occurs if cancer cells do not need testosterone for growth. Symptoms include fatigue, blood in the urine, pain in the hips, back (spine), chest (ribs), or other areas from cancer spread to bones, loss of appetite, or weight loss. Predisposing factors include age, smoking and family history. Treatment includes chemotherapy and radiotherapy.

Report Highlights

Our Pharmaceutical and Healthcare latest pipeline guide Hormone Refractory Prostate Cancer - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Hormone Refractory Prostate Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hormone Refractory Prostate Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 9, 57, 35, 1, 36 and 2 respectively for Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 6, 2, 7 and 4 molecules, respectively for Hormone Refractory Prostate Cancer.

Hormone Refractory Prostate Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Hormone Refractory Prostate Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Hormone Refractory Prostate Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hormone Refractory Prostate Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hormone Refractory Prostate Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hormone Refractory Prostate Cancer (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hormone Refractory Prostate Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hormone Refractory Prostate Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AB Science SA
  • Arno Therapeutics, Inc.
  • CellCentric Ltd
  • G1 Therapeutics, Inc.
  • Johnson & Johnson
  • Orion Oyj
  • MORE
Introduction

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Overview

Therapeutics Development

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Therapeutics under Development by Companies

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Therapeutics under Investigation by Universities/Institutes

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Products Glance

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Products under Development by Companies

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Products under Investigation by Universities/Institutes

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Companies Involved in Therapeutics Development

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Therapeutics Assessment

Drug Profiles

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Dormant Projects

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Discontinued Products

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, H2 2016

Number of Products under Development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Development by Companies, H2 2016 (Contd..1)

Number of Products under Development by Companies, H2 2016 (Contd..2)

Number of Products under Development by Companies, H2 2016 (Contd..3)

Number of Products under Development by Companies, H2 2016 (Contd..4)

Number of Products under Development by Companies, H2 2016 (Contd..5)

Number of Products under Investigation by Universities/Institutes, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Development, H2 2016

Products under Development by Companies, H2 2016

Products under Development by Companies, H2 2016 (Contd..1)

Products under Development by Companies, H2 2016 (Contd..2)

Products under Development by Companies, H2 2016 (Contd..3)

Products under Development by Companies, H2 2016 (Contd..4)

Products under Development by Companies, H2 2016 (Contd..5)

Products under Development by Companies, H2 2016 (Contd..6)

Products under Development by Companies, H2 2016 (Contd..7)

Products under Development by Companies, H2 2016 (Contd..8)

Products under Development by Companies, H2 2016 (Contd..9)

Products under Investigation by Universities/Institutes, H2 2016

Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by AB Science SA, H2 2016

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by AbbVie Inc, H2 2016

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Adamis Pharmaceuticals Corporation, H2 2016

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Advaxis, Inc., H2 2016

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Aeterna Zentaris Inc., H2 2016

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Ambrx, Inc., H2 2016

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Amgen Inc., H2 2016

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by AnGes MG, Inc., H2 2016

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Aphios Corporation, H2 2016

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by ARMO Biosciences, Inc., H2 2016

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Armour Therapeutics Inc., H2 2016

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Arno Therapeutics, Inc., H2 2016

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by ArQule, Inc., H2 2016

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Arrowhead Pharmaceuticals, Inc., H2 2016

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Arvinas, Inc., H2 2016

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Asana BioSciences, LLC, H2 2016

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Astellas Pharma Inc., H2 2016

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by AstraZeneca Plc, H2 2016

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by ATLAB Pharma SAS, H2 2016

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Bavarian Nordic A/S, H2 2016

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Bayer AG, H2 2016

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Bio-Cancer Treatment International Limited, H2 2016

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Biscayne Pharmaceuticals, Inc., H2 2016

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2016

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2016

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by CellCentric Ltd, H2 2016

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Celldex Therapeutics, Inc., H2 2016

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Corcept Therapeutics Incorporated, H2 2016

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Corvus Pharmaceuticals, Inc., H2 2016

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Curevac AG, H2 2016

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by CytoVac A/S, H2 2016

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by DexTech Medical AB, H2 2016

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Eli Lilly and Company, H2 2016

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Enceladus Pharmaceuticals BV, H2 2016

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Endo Pharmaceuticals Inc., H2 2016

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Endocyte, Inc., H2 2016

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Errant Gene Therapeutics, LLC, H2 2016

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by ESSA Pharma Inc, H2 2016

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Fujifilm Corporation, H2 2016

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by G1 Therapeutics, Inc., H2 2016

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Genentech, Inc., H2 2016

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Genmab A/S, H2 2016

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Gilead Sciences, Inc., H2 2016

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Glactone Pharma AB, H2 2016

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by GlaxoSmithKline Plc, H2 2016

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by GTx, Inc., H2 2016

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Hybrigenics S.A., H2 2016

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Immunomedics, Inc., H2 2016

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Io Therapeutics, Inc., H2 2016

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Ionis Pharmaceuticals, Inc., H2 2016

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H2 2016

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Johnson & Johnson, H2 2016

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Jyant Technologies, Inc., H2 2016

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Kura Oncology, Inc., H2 2016

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by MedImmune, LLC, H2 2016

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Mediolanum farmaceutici S.p.A., H2 2016

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Medivation, Inc., H2 2016

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by MEI Pharma, Inc., H2 2016

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Merck KGaA, H2 2016

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Millennium Pharmaceuticals Inc, H2 2016

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by NewLink Genetics Corporation, H2 2016

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Novartis AG, H2 2016

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Oncogenex Pharmaceuticals, Inc., H2 2016

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Oncolytics Biotech Inc., H2 2016

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Oric Pharmaceuticals Inc, H2 2016

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Orion Oyj, H2 2016

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Orphagen Pharmaceuticals, Inc., H2 2016

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Pfizer Inc., H2 2016

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Progenics Pharmaceuticals, Inc., H2 2016

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Selexel, H2 2016

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Sotio a.s., H2 2016

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Supratek Pharma Inc., H2 2016

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Taiho Pharmaceutical Co., Ltd., H2 2016

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Tesaro, Inc., H2 2016

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Tiltan Pharma Ltd., H2 2016

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Tokai Pharmaceuticals, Inc., H2 2016

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by TRACON Pharmaceuticals, Inc., H2 2016

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by UbiVac, LLC, H2 2016

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Viralytics Ltd., H2 2016

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Zenith Capital Corp, H2 2016

Assessment by Monotherapy Products, H2 2016

Assessment by Combination Products, H2 2016

Number of Products by Stage and Target, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Dormant Projects, H2 2016

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Dormant Projects (Contd..1), H2 2016

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Dormant Projects (Contd..2), H2 2016

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Dormant Projects (Contd..3), H2 2016

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Dormant Projects (Contd..4), H2 2016

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Dormant Projects (Contd..5), H2 2016

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Dormant Projects (Contd..6), H2 2016

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Dormant Projects (Contd..7), H2 2016

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Dormant Projects (Contd..8), H2 2016

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Dormant Projects (Contd..9), H2 2016

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Dormant Projects (Contd..10), H2 2016

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Discontinued Products, H2 2016

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Discontinued Products (Contd..1), H2 2016

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Discontinued Products (Contd..2), H2 2016

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Discontinued Products (Contd..3), H2 2016

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Discontinued Products (Contd..4), H2 2016

List of Figures

Number of Products under Development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, H2 2016

Number of Products under Development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Investigation by Universities/Institutes, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Top 10 Targets, H2 2016

Number of Products by Stage and Top 10 Targets, H2 2016

Number of Products by Top 10 Mechanism of Actions, H2 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016

Number of Products by Top 10 Routes of Administration, H2 2016

Number of Products by Stage and Top 10 Routes of Administration, H2 2016

Number of Products by Top 10 Molecule Types, H2 2016

Number of Products by Stage and Top 10 Molecule Types, H2 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
AB Science SA
AbbVie Inc
Adamis Pharmaceuticals Corporation
Advaxis, Inc.
Aeterna Zentaris Inc.
Ambrx, Inc.
Amgen Inc.
AnGes MG, Inc.
Aphios Corporation
ARMO Biosciences, Inc.
Armour Therapeutics Inc.
Arno Therapeutics, Inc.
ArQule, Inc.
Arrowhead Pharmaceuticals, Inc.
Arvinas, Inc.
Asana BioSciences, LLC
Astellas Pharma Inc.
AstraZeneca Plc
ATLAB Pharma SAS
Bavarian Nordic A/S
Bayer AG
Bio-Cancer Treatment International Limited
Biscayne Pharmaceuticals, Inc.
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
CellCentric Ltd
Celldex Therapeutics, Inc.
Corcept Therapeutics Incorporated
Corvus Pharmaceuticals, Inc.
Curevac AG
CytoVac A/S
DexTech Medical AB
Eli Lilly and Company
Enceladus Pharmaceuticals BV
Endo Pharmaceuticals Inc.
Endocyte, Inc.
Errant Gene Therapeutics, LLC
ESSA Pharma Inc
F. Hoffmann-La Roche Ltd.
Fujifilm Corporation
G1 Therapeutics, Inc.
Genentech, Inc.
Genmab A/S
Gilead Sciences, Inc.
Glactone Pharma AB
GlaxoSmithKline Plc
GTx, Inc.
Hybrigenics S.A.
Immunomedics, Inc.
Io Therapeutics, Inc.
Ionis Pharmaceuticals, Inc.
Jiangsu Hengrui Medicine Co., Ltd.
Johnson & Johnson
Jyant Technologies, Inc.
Kura Oncology, Inc.
MedImmune, LLC
Mediolanum farmaceutici S.p.A.
Medivation, Inc.
MEI Pharma, Inc.
Merck KGaA
Millennium Pharmaceuticals Inc
NewLink Genetics Corporation
Novartis AG
Oncogenex Pharmaceuticals, Inc.
Oncolytics Biotech Inc.
Ono Pharmaceutical Co., Ltd.
Oric Pharmaceuticals Inc
Orion Oyj
Orphagen Pharmaceuticals, Inc.
Pfizer Inc.
Progenics Pharmaceuticals, Inc.
Selexel
Sotio a.s.
Supratek Pharma Inc.
Taiho Pharmaceutical Co., Ltd.
Takeda Pharmaceutical Company Limited
Tesaro, Inc.
Tiltan Pharma Ltd.
Tokai Pharmaceuticals, Inc.
TRACON Pharmaceuticals, Inc.
UbiVac, LLC
Viralytics Ltd.
Zenith Capital Corp
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll